证券代码：688796 证券简称：百奥赛图 公告编号：2026-004 百奥赛图（北京）医药科技股份有限公司 关于调整募投项目拟投入募集资金金额的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 百奥赛图（北京）医药科技股份有限公司（以下简称"公司"）于 2026 年 1 月 27 日召开第二届董事会审计委员会 2026 年第一次会议、第二届董事会第十 五次会议，审议通过了《关于调整募投项目拟投入募集资金金额的议案》，公司 中国国际金融股份有限公司（以下简称"保荐人"）对本事项出具了明确无异议 的核查意见，上述事项无需提交股东会审议。现将相关内容公告如下： 一、募集资金基本情况 根据中国证券监督管理委员会（以下简称"中国证监会"）出具的《关于同 意百奥赛图（北京）医药科技股份有限公司首次公开发行股票注册的批复》（证 监许可〔2025〕2296 号），公司首次公开发行人民币普通股（A 股）4,750.00 万股，发行价格 26.68 元/股，募集资金总额人民币 126,730.00 万元，扣除发行 费用后，公司实际募集资金净 ...

证券代码：688796 证券简称：百奥赛图 公告编号：2026-002 百奥赛图（北京）医药科技股份有限公司 关于补选非执行董事及调整专门委员会委员的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 百奥赛图（北京）医药科技股份有限公司（以下简称"公司"）非执行董事 魏义良先生因其他工作安排原因申请辞去公司董事职务，辞职后不再担任公司任 何职务。具体内容详见公司于 2026 年 1 月 1 日在上海证券交易所网站 （www.sse.com.cn）披露的《百奥赛图（北京）医药科技股份有限公司关于公司 非执行董事离任的公告》（公告编号：2026-001）。 为保证公司董事会的规范运作，根据《上海证券交易所科创板股票上市规则》 等法律、法规、规范性文件及《公司章程》的规定，经公司董事会提名委员会资 格审查通过，公司于 2026 年 1 月 27 日召开了第二届董事会第十五次会议，审议 通过了《关于补选公司第二届董事会非执行董事的议案》，同意提名刘弘康先生 （简历详见附件）为公司第二届董事会非执行董事候选人，任期自公司股东会审 议 ...

证券代码：688796 证券简称：百奥赛图 公告编号：2026-008 百奥赛图（北京）医药科技股份有限公司 关于召开2026年第一次临时股东会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （一） 股东会类型和届次 2026年第一次临时股东会 召开日期时间：2026 年 2 月 12 日 14 点 00 分 召开地点：北京市大兴区宝参南街 12 号院 2 号楼 1F-5 会议室 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东会网络投票系统 网络投票起止时间：自2026 年 2 月 12 日 至2026 年 2 月 12 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东会召开当日的交易时间段，即 9:15-9:25，9:30-11:30，13:00-15:00；通过 股东会召开日期：2026年2月12日 本次股东会采用的网络投票系统：上海证券交易所股东会网络投票系统 上述议案已经公司第二届董事会第十五次会议审议通过。相 ...

本次增资实施前，江苏百奥的注册资本为1,111.1111万元人民币，百奥赛图持有江苏百奥100%的股权； 本次增资实施后，江苏百奥的注册资本将增加至17,611.1111万元，公司仍持有江苏百奥100%的股权。 格隆汇1月27日丨百奥赛图(688796.SH)公布，为缓解江苏百奥的资金压力，优化其内部资源配置及资产 负债结构，百奥赛图拟以对江苏百奥55,000万元的债权以债转股的方式，转为对江苏百奥的增资款，其 中16,500万元计入注册资本，38,500万元计入资本公积。相关债权不存在抵押、质押，亦不存在涉及有 关债权的重大争议、诉讼或仲裁事项、查封或者冻结等司法措施。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部份內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 百奧賽圖（北京）醫藥科技股份有限公司 董事長、首席執行官兼執行董事 沈月雷 （股份代號：2315） 暫停辦理H股過戶登記手續 百奧賽圖（北京）醫藥科技股份有限公司（「本公司」）董事（「董事」）會（「董事會」） 謹此宣佈，本公司將於2026年2月12日（星期四）下午二時正假座中國北京市大興 區大興生物醫藥產業基地寶參南街12號院會議室以現場會議結合網上虛擬會議的 方式舉行本公司臨時股東大會（「臨時股東大會」）。 為釐定出席臨時股東大會並於會上投票的權利，本公司將於2026年2月9日（星 期一）至2026年2月12日（星期四）（包括首尾兩日）期間暫停辦理本公司H股（「H 股」）過戶登記手續，期間將不會辦理H股過戶登記。如欲符合資格出席臨時股東 大會並於會上投票，H股持有人須不遲於2026年2月6日（星期五）下午四時三十分 將其過戶文件連同相關股票送達本公司H股股份過戶登記處卓佳證券登記有限公 司（地址為香港 ...

Group 1 - A total of 654 stocks have been newly added to the fund's heavy holdings list, with 12 stocks having a new holding ratio exceeding 3% [1] - Among the newly added stocks, 362 are from the Shanghai and Shenzhen main boards, 186 from the ChiNext, 60 from the Sci-Tech Innovation Board, and 45 from the Beijing Stock Exchange [1] - The sectors with the highest number of newly added stocks include machinery equipment, basic chemicals, and electronics, with 83, 65, and 63 stocks respectively [1] Group 2 - The stock with the highest new holding ratio is Bai'ao Saitou, which was included in 53 fund heavy holdings with a total holding of 7.7342 million shares, accounting for 21.55% of its circulating shares [2] - Li Tong Technology follows with 11 funds holding a total of 10.4283 million shares, representing 12.60% of its circulating shares [2] - Other notable stocks with high holding ratios include Xingtu Measurement and Control, Chaojie Co., Ltd., and Dafeng Industrial, with holding ratios of 10.03%, 7.36%, and 4.84% respectively [2] Group 3 - Stocks with high new holdings have seen an average increase of 58.85% since the fourth quarter of last year, with notable gainers including Chaojie Co., Ltd. (285.08%), Qianyan Biology-U (80.32%), and Lixing Co., Ltd. (77.77%) [3] - Bai'ao Saitou is expected to report a net profit increase of 303.57%, with a median net profit forecast of 135 million yuan [3] - The stocks with the highest number of funds holding them include Biobetter-U with 72 funds, Bai'ao Saitou with 53 funds, and Xingtu Measurement and Control with 30 funds [2][3]

Market Overview - The medical services sector increased by 0.18% on January 21, with Nanmo Biology leading the gains [1] - The Shanghai Composite Index closed at 4116.94, up 0.08%, while the Shenzhen Component Index closed at 14255.12, up 0.7% [1] Top Gainers in Medical Services - Nanmo Biology (688265) closed at 49.79, up 7.01% with a trading volume of 20,000 shares and a transaction value of 98.02 million [1] - Hite Biology (300683) closed at 29.67, up 5.74% with a trading volume of 107,800 shares and a transaction value of 32.2 million [1] - Dean Diagnostics (300244) closed at 26.46, up 5.59% with a trading volume of 796,300 shares and a transaction value of 2.13 billion [1] - ST Zhongzhu (600568) closed at 2.64, up 5.18% with a trading volume of 376,500 shares and a transaction value of 9.81 million [1] - Tongce Medical (600763) closed at 46.51, up 4.99% with a trading volume of 198,600 shares and a transaction value of 911 million [1] Top Losers in Medical Services - Digital Human (920670) closed at 18.72, down 4.44% with a trading volume of 74,500 shares and a transaction value of 143 million [2] - Hongbo Pharmaceutical (301230) closed at 46.36, down 1.88% with a trading volume of 131,200 shares and a transaction value of 614 million [2] - Chengda Pharmaceutical (301201) closed at 41.39, down 1.76% with a trading volume of 36,600 shares and a transaction value of 153 million [2] Capital Flow in Medical Services - The medical services sector saw a net inflow of 50.51 million from institutional investors, while retail investors experienced a net outflow of 375 million [2] - The sector's overall capital flow indicates a strong interest from institutional and speculative investors, with retail investors pulling back [2][3] Notable Capital Inflows - Sanbo Brain Science (301293) had a net inflow of 91.48 million, representing 9.03% of its total capital [3] - Tongce Medical (600763) saw a net inflow of 83.46 million, accounting for 9.16% of its total capital [3] - BGI Genomics (300676) recorded a net inflow of 51.81 million, which is 8.37% of its total capital [3]

Core Viewpoint - The company has successfully localized its AI-driven antibody drug development platform, enhancing collaboration with its core business, the "Thousand Mice and Ten Thousand Antibodies" initiative [1] Group 1: Company Developments - The company’s stock has seen a significant increase, rising nearly 7% and currently trading at 39.72 HKD with a transaction volume of 28.32 million HKD [1] - The localization of the AI platform aims to build an intelligent system for antibody drug development, which is expected to improve efficiency in preclinical PCC molecule development for global pharmaceutical partners [1] Group 2: Strategic Initiatives - The integration of the "Thousand Mice and Ten Thousand Antibodies" plan with the AI system is ongoing, which will provide pharmaceutical companies with more efficient research tools and a richer library of antibody molecules [1] - This strategic move is anticipated to propel the antibody discovery business into a new phase of development [1]

Core Viewpoint - Baiaosaitu-B (02315) has seen a significant increase in stock price, rising nearly 7% and currently trading at 39.72 HKD, with a transaction volume of 28.32 million HKD. The company has completed the localization of its AI-driven antibody drug development platform, enhancing synergy with its core business, the "Thousand Mice and Ten Thousand Antibodies" initiative [1]. Group 1 - The company has successfully localized its AI-driven antibody drug development platform [1]. - The integration of the AI system with the "Thousand Mice and Ten Thousand Antibodies" plan is ongoing, which is expected to provide more efficient research tools and a richer antibody molecule library for global pharmaceutical companies [1]. - This development aims to improve the efficiency of preclinical PCC molecule research for pharmaceutical partners, marking a new phase in the antibody discovery business [1].

Core Viewpoint - 62 companies listed on the Sci-Tech Innovation Board have provided earnings forecasts for 2025, with 21 companies expecting losses, 20 expecting profit increases, 14 expecting reduced losses, 5 expecting profit declines, and 2 expecting profits [1]. Group 1: Earnings Forecasts - Among the 62 companies, 20 are expected to increase profits, and 2 are expected to be profitable, resulting in a total of 35.48% of companies reporting positive forecasts [1]. - The companies with the highest expected profit growth include Baiwei Storage with a median profit increase of 473.71%, followed by Zhongke Lanyun at 371.51% and Baiaosaitu at 303.57% [1][3]. - Industries with significant profit growth include electronics, machinery, and biomedicine, with 7, 4, and 3 companies respectively showing profit increases of over 50% [1]. Group 2: Stock Performance - Sci-Tech Innovation Board stocks with high earnings growth have averaged a 17.21% increase in stock price this year [1]. - Baiwei Storage has seen the largest stock price increase of 65.85%, followed by Qiangyi Co. and Oke Yi with increases of 45.25% and 30.53% respectively [1]. Group 3: Capital Flow - In terms of capital flow, stocks with significant earnings growth have seen net inflows, with Lankai Technology, Dingtong Technology, and Baiwei Storage receiving net inflows of 569 million, 342 million, and 199 million respectively over the past five days [2]. - Conversely, stocks like Qiangyi Co., Zhongke Lanyun, and Baiaosaitu have experienced net outflows of 185 million, 114 million, and 99.92 million respectively [2].